In the case of pancreatic cancer, more than 90% of pancreatic adenocarcinomas show mutations in the KRAS gene which result in constitutively active Ras, which can affect the activation of the ERK MAPK pathway [42-44]. This evidence concerns the gene KRAS and pancreatic neoplasm.